IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza signs agreement with Index Ventures for development and manufacture of biologics

12:04 AM MST | January 9, 2014 | Deepti Ramesh

Lonza and Index Ventures, a leading venture capital investment firm, have signed an exclusive five-year agreement for process development and cGMP production for all biological products in the portfolio of companies where Index Ventures is the major investor. Additional development and manufacturing projects will be added to the product list over the course of the agreement as future investments are made by Index Ventures, Lonza...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa